Clinical Convergence® Unresectable HCC: An Emerging Era of Combination Therapy

Program Overview

In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.

You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.

Credit Expired
CE Credit Expired
Expires: December 28, 2021

Target Audience

This activity is intended for hepatology, hematology/oncology, and other clinicians including physicians, NPs, and PAs who diagnose and manage patients with hepatocellular carcinoma (HCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data
  • Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy
  • Analyze the safety and efficacy of new and emerging combination regimens for HCC


Activity Faculty


Richard S. Finn, MD

Professor, Department of Medicine​
Division of Hematology/Oncology​
UCLA David Geffen School of Medicine ​
Director, Signal Transduction and Therapeutics Program​
Jonsson Comprehensive Cancer Center ​
University of California ​
Los Angeles, CA


Amit Singal, MD, MS  

David Bruton Jr. Professor, Clinical Cancer Research
Professor, Medicine
Chief and Medical Director, Liver Tumor Program
UT Southwestern Medical Center
Dallas, TX


Mark Yarchoan, MD

Assistant Professor, Division of GI Malignancies
Medical Oncology Director, Liver Cancer Multidisciplinary Clinic
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, MD

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources